Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fujifilm Gets 10%-plus Stake in Australian Cell Therapy Startup
September 6, 2016
- Sato, Fuso to Copromote Emla Cream for Dialysis Patients
September 6, 2016
- Hisamitsu Starts PIII Trial of Transdermal Schizophrenia Treatment in US
September 6, 2016
- Celgene Seeks Japan Approval of Romidepsin for PTCL
September 6, 2016
- Merck Ditches Osteoporosis Med Odanacatib from Global Pipelines
September 6, 2016
- Sanofi’s PCSK9 Inhibitor Praluent Now Available in Japan
September 6, 2016
- Shionogi Takes Osaka Tax Bureau to Court
September 5, 2016
- Takeda to Develop Zika Vaccine with US Funding
September 5, 2016
- MSD Paid 15.2 Billion Yen to Doctors, Medical Institutions in 2015
September 5, 2016
- Oncolys to Evaluate Oncolytic Virus in Combination with Immune Checkpoint Inhibitors; Interim Results Expected in 2017
September 5, 2016
- Nippon Kayaku Seeks Add’l Dosage for Remicade Biosimilar in Psoriasis
September 2, 2016
- Takeda Kicks Off Global Observation Study for Multiple Myeloma
September 2, 2016
- Lilly, Osaka Univ. Join Forces on Obesity Research
September 2, 2016
- Chugai Transfers Marketing Authorization for Vesanoid to Fuji Pharma
September 2, 2016
- Sunovion to Acquire Canadian CNS Biotech: Sumitomo Dainippon
September 2, 2016
- Kipres/Singulair AG Hits Shelves in Japan: Kyorin Holdings
September 2, 2016
- Sandoz Taps Jason Hoffe as New Japan Head
September 2, 2016
- Otsuka, RIKEN Open Collaborative Research Center to Promote Regenerative Medicine
September 2, 2016
- Takecab Most Heavily Pitched Drug in July: Anterio
September 1, 2016
- Sovaldi Filed in Japan for All Hep C Genotypes Excluding Genotype 1: Gilead
September 1, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…